ETNB
Price:
$8.47
Market Cap:
$897.06M
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2019-11-11
Stock Exchange
NASDAQ
Ticker
ETNB
According to 89bio, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 13.92. This represents a change of -17.16% compared to the average of 16.81 of the last 4 quarters.
The mean historical Current Ratio of 89bio, Inc. over the last ten years is 13.63. The current 13.92 Current Ratio has changed 10.11% with respect to the historical average. Over the past ten years (40 quarters), ETNB's Current Ratio was at its highest in in the December 2020 quarter at 25.91. The Current Ratio was at its lowest in in the September 2018 quarter at 0.
Average
13.63
Median
12.64
Minimum
2.60
Maximum
25.91
Discovering the peaks and valleys of 89bio, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 553.76%
Maximum Annual Current Ratio = 25.91
Minimum Annual Increase = -68.00%
Minimum Annual Current Ratio = 2.60
Year | Current Ratio | Change |
---|---|---|
2023 | 20.04 | 151.62% |
2022 | 7.97 | -3.92% |
2021 | 8.29 | -68.00% |
2020 | 25.91 | 52.45% |
2019 | 17.00 | 553.76% |
The current Current Ratio of 89bio, Inc. (ETNB) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
12.10
5-year avg
15.84
10-year avg
13.63
89bio, Inc.’s Current Ratio is greater than Madrigal Pharmaceuticals, Inc. (8.72), less than Pliant Therapeutics, Inc. (14.47), greater than Arcellx, Inc. (6.01), greater than Stoke Therapeutics, Inc. (6.67), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Inozyme Pharma, Inc. (9.84), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Mereo BioPharma Group plc (6.07), less than Viking Therapeutics, Inc. (37.69), greater than Intercept Pharmaceuticals, Inc. (4.22), less than Terns Pharmaceuticals, Inc. (21.02), less than Akero Therapeutics, Inc. (24.89), greater than Reata Pharmaceuticals, Inc. (3.21), greater than HOOKIPA Pharma Inc. (3.86), greater than TG Therapeutics, Inc. (3.58), greater than Hepion Pharmaceuticals, Inc. (5.62),
Company | Current Ratio | Market cap |
---|---|---|
8.72 | $5.30B | |
14.47 | $782.51M | |
6.01 | $3.83B | |
6.67 | $773.92M | |
4.09 | $1.25B | |
6.07 | $109.78M | |
9.84 | $312.42M | |
17.37 | $133.38M | |
6.07 | $664.26M | |
37.69 | $6.00B | |
4.22 | $794.69M | |
21.02 | $549.60M | |
24.89 | $1.83B | |
3.21 | $6.57B | |
3.86 | $159.50M | |
3.58 | $3.41B | |
5.62 | $4.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 89bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 89bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is 89bio, Inc.'s Current Ratio?
How is the Current Ratio calculated for 89bio, Inc. (ETNB)?
What is the highest Current Ratio for 89bio, Inc. (ETNB)?
What is the 3-year average Current Ratio for 89bio, Inc. (ETNB)?
What is the 5-year average Current Ratio for 89bio, Inc. (ETNB)?
How does the current Current Ratio for 89bio, Inc. (ETNB) compare to its historical average?